Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Tesla, Inc. — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.65 (market cap $977.37M), while Tesla, Inc. trades at $361.16 (market cap $1.45T). The key difference: Tesla, Inc. is far larger — about 1483.6× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Tesla, Inc. for 88 Days on average.
| MRVI | TSLA | |
|---|---|---|
Market Cap | $977.37M | $1.45T |
Volume | 2,742,564 | 30,868,569 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.00 | $489.88 |
52-Week Low | $2.83 | $298.16 |
Typical Hold Time | 0 Days | 88 Days |
Enterprise Value | $1.08B | $1.42T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Tesla (TSLA) trades at $375.20, down 0.75% on the day amid mixed signals. The stock shows a bullish technical trend with strong moving averages but faces overbought RSI warnings. Fundamentally, revenue dipped to $94.83B in 2025 with net income margin at 3.67%, while valuation ratios remain elevated with a P/E of 339.96. Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch, balancing delivery misses and competitive pressures.
Tesla's outlook hinges on executing its pivot to AI and autonomy, with a consensus price target of $441.36 offering 18% upside. However, high valuations, slowing auto growth, and execution risks in new ventures pose significant challenges. Investors should weigh the long-term potential of robotaxis and energy against near-term profitability concerns and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
